Asn45-Ile213 with Human IgG1 Fc Tag at N-Terminus
50-60kDa (Reducing)
Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation.
· 12 months from date of receipt, lyophilized powder stored at -20 to -80℃.
· 3 months, -20 to -80℃ under sterile conditions after reconstitution.
· 1 week, 2 to 8℃ under sterile conditions after reconstitution.
· Please avoid repeated freeze-thaw cycles.
Wu P, et al. TLR9/TLR7-triggered downregulation of BDCA2 expression on human plasmacytoid dendritic cells from healthy individuals and lupus patients. Clin Immunol. 2008,
Lim SM, et al. CLEC4C p.K210del variant causes impaired cell surface transport in plasmacytoid dendritic cells of amyotrophic lateral sclerosis. Oncotarget. 2016
Robak E, Braun M, Robak T. Leukemia Cutis-The Current View on Pathogenesis, Diagnosis, and Treatment. Cancers (Basel). 2023,
Wilson NR, et al. CD303 (BDCA-2) - a potential novel target for therapy in hematologic malignancies. Leuk Lymphoma. 2022,
5. Riboldi E, et al. Human C-type lectin domain family 4, member C (CLEC4C/BDCA-2/CD303) is a receptor for asialo-galactosyl-oligosaccharides. J Biol Chem. 2011
Dendritic Cell Lectin (DLEC), also known as BDCA-2, CD303, HECL, and alternatively designated as CLEC4C/CLECSF11/CLECSF7, is a 38 kDa type II transmembrane protein belonging to the C-type lectin family. The expression of DLEC is primarily restricted to plasmacytoid dendritic cells (pDCs) and is downregulated as these cells mature.
pDCs are integral to the innate immune response, particularly in the production of IFN-alpha/beta upon exposure to Toll-like receptor (TLR) 7 and TLR9 agonists, such as microbial CpG DNA. The ligation of DLEC on pDCs with specific antibodies has been shown to attenuate the CpG-stimulated production of interferons and to bias the response towards a Th1 phenotype.
Monoclonal antibodies targeting CLEC4C have demonstrated disease control in patients with cutaneous lupus erythematosus. The modulation of IFN-alpha production mediated by CLEC4C is regulated through the masking and unmasking of galactose moieties on the lectin. This mechanism represents a novel potential strategy for modulating immune responses in various pathological conditions.
1μg (R: reducing condition, N: non-reducing condition).
Immobilized Purified anti-human CD303 (BDCA-2) Antibody at 2.0μg/mL (100μL/well) can bind BDCA2/DLEC4C Fc Chimera Protein, Human (Cat. No. UA011101) with EC50 of 0.81-1.40 ng/mL.
您现在的位置：